Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-26.03%
operating margin TTM
-31.21%
revenue TTM
88.34 Million
revenue per share TTM
1.94$
valuation ratios | |
|---|---|
| pe ratio | -17.56 |
| peg ratio | -0.80 |
| price to book ratio | 4.46 |
| price to sales ratio | 4.58 |
| enterprise value multiple | -17.04 |
| price fair value | 4.46 |
profitability ratios | |
|---|---|
| gross profit margin | 81.55% |
| operating profit margin | -31.21% |
| pretax profit margin | -26.49% |
| net profit margin | -26.03% |
| return on assets | -18.96% |
| return on equity | -24.6% |
| return on capital employed | -28.27% |
liquidity ratios | |
|---|---|
| current ratio | 4.00 |
| quick ratio | 3.58 |
| cash ratio | 2.71 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 225.19 |
| operating cycle | 292.48 |
| days of payables outstanding | 175.42 |
| cash conversion cycle | 117.05 |
| receivables turnover | 5.42 |
| payables turnover | 2.08 |
| inventory turnover | 1.62 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | 0.04 |
| long term debt to capitalization | 0.03 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -5.70 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.40 |
| cash per share | 1.37 |
| operating cash flow per share | -0.39 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -5.70 |
| short term coverage ratios | -36.62 |
| capital expenditure coverage ratio | -140.12 |
Frequently Asked Questions
When was the last time Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) reported earnings?
Y-mAbs Therapeutics, Inc. (YMAB) published its most recent earnings results on 08-08-2025.
What is Y-mAbs Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s trailing twelve months ROE is -24.6%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Y-mAbs Therapeutics, Inc. (YMAB) currently has a ROA of -18.96%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did YMAB's net profit margin stand at?
YMAB reported a profit margin of -26.03% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is YMAB's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.00 in the most recent quarter. The quick ratio stood at 3.58, with a Debt/Eq ratio of 0.04.